The Company
All Model Pty Ltd is an Australian technology company building products and therapeutics from a single mathematical discovery: one equation that works for all models.
The company operates across two primary areas. The first is the development and commercialisation of the All Model equation itself — a universal mathematical model with applications in physics, chemistry, electronics, finance and life sciences. The second is a pharmaceutical platform that emerged directly from the life sciences application of that equation: novel opsin protein therapeutics for inherited retinal diseases.
The Founder
All Model Pty Ltd was founded by Burzin Bhavnagri, who discovered the All Model equation in 1996. The discovery arose from an observation that a single mathematical structure could produce valid results across fundamentally different model types — without needing to specify or derive the underlying model in advance.
Bhavnagri has since applied the equation across multiple domains, with the pharmaceutical application — targeting molecules within the visual cycle to develop treatments for conditions such as Leber Congenital Amaurosis, Stargardt disease and Retinitis Pigmentosa — representing the most commercially advanced expression of the technology to date.
The Mission
All Model Pty Ltd exists to turn one fundamental discovery into useful things: technology that works across fields, and medicines that address conditions for which no effective treatment currently exists. The company believes that genuine scientific differentiation — not incremental improvement on existing approaches — is both the most defensible commercial position and the most direct path to real-world impact.
In the pharmaceutical context, this means pursuing a peptide and small molecule approach to vision cycle disorders at a time when every competitor is using AAV gene therapy — a structurally different method with its own limitations in terms of re-dosing, immunogenicity, and manufacturing complexity.
In the broader technology context, it means continuing to explore and apply the All Model equation to new model domains where the ability to work without specifying the underlying model provides a meaningful advantage.
RecoverSight
The pharmaceutical division operates under the brand RecoverSight. Two novel retinal analog compounds — 8-0-3b and 3-0-8a — are currently available for research use. Both are patent pending worldwide. RecoverSight is pursuing registration through the TGA Orphan Drug Program, which provides priority review, reduced fees, and ten years of market exclusivity for treatments targeting rare conditions.
Based in Australia
All Model Pty Ltd is incorporated in Australia and conducts its research and development from Australia. The company is eligible for R&D tax incentives under the Australian Government's Research and Development Tax Incentive programme, and its pharmaceutical pipeline qualifies for the TGA Orphan Drug Program.
All Model Pty Ltd is actively seeking investment partners and research collaborators. The company's technology platform, open intellectual property position in the small molecule opsin space, and Orphan Drug eligibility represent a compelling early-stage opportunity in one of ophthalmology's fastest-growing market segments.